Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | RGS12 | O14924 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10346709 | 1.00 | CA1 (0.52) | CA1CA2SRCLMNAMAPK1 | |
| SCHEMBL10346708 | 1.00 | CA1 (0.52) | CA1CA2SRCLMNAMAPK1 | |
| SCHEMBL10778817 | 0.86 | LMNA (0.42) | CA1CA2LMNAKMT2AMEN1 | |
| SCHEMBL10778827 | 0.86 | LMNA (0.42) | CA1CA2LMNAKMT2AMEN1 | |
| SCHEMBL8082651 | 0.84 | BRD4 (0.43) | CA1CA2KMT2AMEN1TSHR | |
| SCHEMBL14278787 | 0.83 | SRC (0.48) | SRCLMNAMAPK1KMT2AMEN1 | |
| SCHEMBL4799364 | 0.83 | SRC (0.48) | SRCLMNAMAPK1KMT2AMEN1 | |
| SCHEMBL762079 | 0.83 | SRC (0.48) | SRCLMNAMAPK1KMT2AMEN1 | |
| SCHEMBL10346863 | 0.82 | PTGS1 (0.57) | KMT2AMEN1CYP2D6MTNR1AMTNR1B | |
| SCHEMBL10346862 | 0.82 | PTGS1 (0.57) | KMT2AMEN1CYP2D6MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920342-B2 | Process for the preparation of Droxidopa | DIVI'S LABORATORIES LIMITED | 2018-03-20 | — | — | US | disclosed |
| US-20170335357-A1 | PROCESS FOR THE PREPARATION OF DROXIDOPA | DIVI'S LABORATORIES LIMITED (IN) | 2017-11-23 | — | — | US | disclosed |
| US-20170335357-A1 | PROCESS FOR THE PREPARATION OF DROXIDOPA | DIVI'S LABORATORIES LIMITED (IN) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170335357-A1 | PROCESS FOR THE PREPARATION OF DROXIDOPA | DAO, DDO, DNPEP | CA1 365/4885CA2 385/4885SRC 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.